Separately, Zacks Investment Research cut shares of Erytech Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, March 6th.
ERYP stock opened at $7.51 on Wednesday. The stock has a market cap of $134.71 million, a PE ratio of 3.08 and a beta of 1.70. The company has a current ratio of 7.26, a quick ratio of 7.19 and a debt-to-equity ratio of 0.01. Erytech Pharma has a 1 year low of $5.45 and a 1 year high of $20.00.
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Further Reading: How do candlesticks reflect price movement?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.